Breast Carcinoma Clinical Trial
Official title:
Targeted Prevention of Postpartum-Related Breast Cancer
Verified date | June 2024 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) patients with benign breast disease planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | January 30, 2027 |
Est. primary completion date | January 30, 2026 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - PRE-REGISTRATION: Age >= 18 years and =< 45 years of age - PRE-REGISTRATION: Presence of lesion suspicious for benign breast disease and planned breast biopsy or planned mammoplasty or other breast surgery (e.g., breast reduction, breast implants, etc.) or willing to have research biopsy or breast biopsy = 12 months prior to pre-registration for benign breast disease with tissue available for research. - PRE-REGISTRATION: Had a live birth =< 10 years prior to pre-registration - PRE-REGISTRATION: Pre-menopausal according to patient report and/or clinical determination - PRE-REGISTRATION: Provide written informed consent - PRE-REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance - PRE-REGISTRATION: Willingness to provide mandatory blood and urine specimens for correlative research - PRE-REGISTRATION: Willingness to provide mandatory tissue specimens for correlative research - REGISTRATION: Age >= 18 years and =< 45 years of age - REGISTRATION: Histological confirmation of benign breast disease (i.e., no evidence of DCIS or invasive cancer) - REGISTRATION: Registration for this study must be completed either =< one (1) year after the qualifying pre-registration biopsy performed for this study or =< one (1) year after collection of the archived tissue (for those who did not have a pre-registration biopsy performed after pre-registration for this study) - REGISTRATION: Hemoglobin >= 9.0 g/dL (obtained =< 30 days prior to registration) - REGISTRATION: Platelet count >= 100,000/mm^3 (obtained =< 30 days prior to registration - REGISTRATION: Serum creatinine =< 2.0 mg/dl (obtained =< days prior to registration) - REGISTRATION: Negative pregnancy test done =< 14 days prior to registration - REGISTRATION: Willing to use contraception while on treatment - REGISTRATION: Provide written informed consent - REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance - REGISTRATION: Willingness to provide mandatory blood and urine specimens for correlative research - REGISTRATION: Willingness to provide mandatory tissue specimens for correlative research - REGISTRATION: Willing to return to enrolling institution for follow-up - REGISTRATION: Known or suspected active breast infection Exclusion Criteria: - PRE-REGISTRATION: History of breast cancer including ductal breast carcinoma in situ (DCIS) - PRE-REGISTRATION: Received systemic treatment for any other cancer at any time - PRE-REGISTRATION: Currently taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDS) (no doses within =< 5 days prior to pre-registration and no more than eight doses within =< 30 days prior to pre-registration) - PRE-REGISTRATION: Currently taking other agents for the prevention of breast cancer - PRE-REGISTRATION: Currently taking anticoagulants - PRE-REGISTRATION: Contraindication for aspirin use - PRE-REGISTRATION: Known or suspected active breast infection - REGISTRATION: No research tissue available from pre-registration biopsy or from archived tissue (collected =< 12 months prior to pre-registration) - REGISTRATION: Currently taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) (NOTE: no doses within =< 5 days prior to registration and no more than four doses within =< 30 days prior to registration) - REGISTRATION: Co-morbid illnesses/conditions which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens - REGISTRATION: Any contraindication to aspirin use including but not limited to: - Bleeding disorders (e.g., hemophilia) - Stomach or intestinal bleeding =< 6 months prior to registration - Known allergy to other non-steroidal anti-inflammatory drugs (NSAIDs) - REGISTRATION: Currently taking anticoagulants - REGISTRATION: Any prior or current malignancy requiring prior or current systemic therapy - REGISTRATION: Currently pregnant or planning to become pregnant in the next 90 days - REGISTRATION: Post-menopausal: - Prior bilateral surgical oophorectomy or - No menses for > 1 year with estradiol levels within postmenopausal range, according to institutional standard - Known or suspected active breast infection |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Florida | Jacksonville | Florida |
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
United States | Mayo Clinic in Arizona | Scottsdale | Arizona |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in percent of epithelial cells positive for COX-2, estrogen receptor (ER)/Ki67, gammaH2AX, and p16 in "normal" and in benign breast disease (BBD) lobules | Will be calculated based on pre- and post-intervention for each person. Within person differences will be analyzed. The correlation between the change in PRBC score and change in PPI signature will be assessed using a Pearson correlation if both the scores are normally distributed. If either score is non-normally distributed, a Spearman correlation will be used instead. The correlation coefficient point estimate and 95% confidence interval will be reported. | Pre- vs. post-intervention up to 30 days | |
Other | Change in serum C-reactive protein (CRP), estrogens, insulin/insulin-like growth factors (IGFs), and adipokines | Will be measured pre- and post-intervention for each person. Within person differences will be analyzed. The correlation between the change in PRBC score and change in the respective serum measures will be assessed using a Pearson correlation if both the values are normally distributed. If either value is non-normally distributed, a Spearman correlation will be used instead. The correlation coefficient point estimate and 95% confidence interval will be reported. | Pre- vs. post-intervention up to 30 days | |
Other | Changes in tissue and urine prostaglandins (PGs) and PGE2 | Will be measured pre- and post-intervention for each person. Within person differences will be analyzed. The correlation between the change in PRBC score and change in the respective PGs will be assessed using a Pearson correlation if both the values are normally distributed. If either value is non-normally distributed, a Spearman correlation will be used instead. The correlation coefficient point estimate and 95% confidence interval will be reported. | Pre- vs. post-intervention up to 30 days | |
Primary | Change in pregnancy-related breast cancer (PRBC) score | Will transform the biomarkers using Van der Waerden rank transformations. Will analyze data as within person differences for pre- versus post-treatment PRBC scores in tissues. The final mean difference in PRBC score point estimate and corresponding 95% confidence interval will be reported. | Pre- versus (vs) post-intervention up to 30 days | |
Secondary | Change in postpartum involution (PPI) signature score | Will be calculated pre- and post-intervention for each person. Within person differences will be analyzed. The correlation between the change in PRBC score and change in PPI signature will be assessed using a Pearson correlation if both the scores are normally distributed. If either score is non-normally distributed, a Spearman correlation will be used instead. The correlation coefficient point estimate and 95% confidence interval will be reported. | Pre- vs. post-intervention up to 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04996316 -
MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals
|
||
Enrolling by invitation |
NCT05558917 -
Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery
|
N/A | |
Completed |
NCT05526872 -
A Patient Reminder and Self-Referral Via Online Patient Portals and Text Messaging to Improve Adherence to Breast Cancer Screening
|
N/A | |
Not yet recruiting |
NCT05178498 -
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
|
||
Recruiting |
NCT05544123 -
The Treatment Situation of Chinese County Population With Breast Cancer
|
||
Withdrawn |
NCT05191004 -
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
|
Phase 1/Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Recruiting |
NCT01462903 -
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
|
Phase 1 | |
Completed |
NCT01422408 -
Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy
|
Phase 2 | |
Terminated |
NCT02810873 -
Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer
|
N/A | |
Terminated |
NCT00770354 -
Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT03185871 -
Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses
|
Phase 2 | |
Completed |
NCT02983279 -
Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer
|
N/A | |
Active, not recruiting |
NCT02194387 -
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
|
N/A | |
Recruiting |
NCT05406232 -
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
|
||
Recruiting |
NCT03408353 -
Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study
|
||
Completed |
NCT01641068 -
Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms
|
N/A | |
Withdrawn |
NCT04190433 -
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
|
Phase 2 | |
Recruiting |
NCT04799535 -
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
|
||
Terminated |
NCT02923037 -
Hatha Yoga in Breast Cancer Survivors
|
N/A |